Treating people with cardiovascular disease and COPD causes significant clinician anxiety.
β-Blockers save lives in people with heart disease, specifically postinfarction and heart …

Highlights•Selective BBs in COPD were not associated with relevant worsening of
pulmonary function.•Selective BBs could be used in COPD with CVD comorbidities.•In …

The combined effects on the heart of smoking and hypoxaemia may contribute to an
increased cardiovascular burden in chronic obstructive pulmonary disease (COPD). The use …

Extensive randomised clinical trial (datasupportthe view that β-blockers have a significant
impact opífdíQpd s of patients with cardiovascular disease, especially those with coronary …

The mortality and incidence of chronic obstructive pulmonary disease (COPD) and coronary
heart disease increase with age. Despite the clear evidence of beta blockers (BBs) …

Background β-Adrenergic agonists exert physiologic effects that are the opposite of those of
β-blockers. β-Blockers are known to reduce morbidity and mortality in patients with cardiac …

Background Cardiovascular disease is a frequent comorbidity in patients with COPD. Many
physicians, particularly pulmonologists, are reluctant to use β-adrenoceptor blocking agents …

OBJECTIVE: To evaluate the safety and cardiovascular benefits of β-blocker therapy in
patients with chronic obstructive pulmonary disease (COPD). DATA SOURCES: Clinical …

Introduction β-Blockers are known to worsen FEV 1 and airway hyperresponsiveness (AHR)
in patients with asthma. Both characteristics determine the outcome of COPD, a disease with …

Rationale: Cardiovascular disease is a common comorbidity in patients with chronic
obstructive pulmonary disease. Although β-blockers can be used safely in patients with …